

Date: 12th February, 2020

To
The Secretary
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai - 400001

Company Code No: 532771

To
The Secretary
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra East, Mumbai-400 051

NSE Symbol: JHS

Dear Sir/Madam,

Subject: Submission of Copies of Published Unaudited Standalone and Consolidated Financial Results of the Company

In Continuation of our letter dated February, 11, 2020, we enclose copies of the newspapers in which Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December, 31, 2019 were published on February, 12, 2020 in Business Standard (English) and Naya India (Hindi).

This is for your information and record purpose.

Thanking you

Yours sincerely
For JHS Svendgaard Laboratories Limited


Chetan Batra
Company Secretary & Compliance Officer
MNo. A30039





JHS SVENDGAARD LABORATORIES LIMITED

Regd Office : Trilokpur Road, Kheri (Kala-amb), Tehsil-Nahan, Distt. Sirmour, Himachal Pradesh-173030, INDIA

CIN - L24230HP2004PLC027556

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine Months Ended 31st December, 2019

Particulars	Quarter Ended 31 st Dec 2019	Quarter Ended 30 th Sept 2019	Quarter Ended 31 st Dec 2018	Nine Months Ended 31 st Dec 2019	Nine Months Ended 31 st Dec 2018	Year Ended 31 st March 2019	(Rs in lacs)
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Total income from operations	3,911.13	3,772.20	3,904.74	10,387.42	9,215.01	13,077.78	
Net Profit / (Loss) for the period (before tax, exceptional item and/or extraordinary items)	(3.86)	(98.09)	126.31	(203.13)	(49.10)	(204.50)	
Net Profit / (Loss) for the period (before tax after exceptional and/or extraordinary items)	(3.86)	(98.09)	126.31	(203.13)	(49.10)	(204.50)	
Net Profit/(Loss) for the period (after tax exceptional and/or extraordinary items)	38.40	(194.27)	58.27	(232.56)	(97.50)	(166.73)	
Total comprehensive income for the period	40.16	(192.52)	58.69	(227.30)	(96.29)	(159.71)	
Equity Share Capital (Face value of Rs 10 each)	6,090.05	6,090.05	6,090.05	6,090.05	6,090.05	6,090.05	
Reserves (Excluding Revaluation Reserves)						11,594.48	
Earnings per equity share (of Rs 10 each)							
(a) Basic (Rs)	0.11	(0.09)	0.10	(0.03)	(0.16)	(0.11)	
(b) Diluted (Rs)	0.11	(0.09)	0.10	(0.03)	(0.16)	(0.11)	

Key numbers of Standalone Financial Results

Particulars	Quarter Ended 31 st Dec 2019	Quarter Ended 30 th Sept 2019	Quarter Ended 31 st Dec 2018	Nine Months Ended 31 st Dec 2019	Nine Months Ended 31 st Dec 2018	Year Ended 31 st March 2019	
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
Total income from operations	3,682.13	3,576.51	3,728.46	9,718.34	8,896.48	12,543.67	
Profit / (Loss) for the period (after extraordinary activities but before tax)	132.46	168.50	264.94	374.42	396.22	521.88	
Profit / (Loss) for the period (after extraordinary activities and tax)	152.71	88.39	157.36	287.70	231.81	360.18	
Total comprehensive income for the period	154.07	89.74	157.78	291.76	233.02	365.60	

Notes: The above is an extract of the detailed format of Financial Results for the quarter and nine months ended filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Financial Results for the quarter and nine months ended 31st December 2019 are available at the website of the BSE (www.bseindia.com) and NSE (www.nseindia.com) and also on company website www.svendgaard.com.

For and behalf of
For JHS Svendgaard Laboratories Limited
Sd/-
Nikhil Nanda
Managing Director
DIN 00051501

Date : 11th February 2020

Place : New Delhi

HIP C
TOMA

1. Tot
2. Net
(be)
3. Net
befor
Extin
4. Net
afte
Extin
5. Total
per
for
Con
6. Equ
(Fai
7. Oth
8. Equ
(Fai
1. B
2. C
* Oth

Note:
1. The
review
meetin
unaud
2019.
2. The
quarte
Regula
The fu
availab
websit

Place:
Date:

